Skip to main content

Table 4 Safety profile of omalizumab-assisted oral immunotherapy

From: Omalizumab in children with severe allergic disease: a case series

Patient Symptoms Concomitant Trigger Milk (mL) OIT step Emergency treatment Outcome
3 Rhinitis No 120 18th week (OIT) Antihistamine Failed
Rhinitis and asthma Acute illness 100 20th week (OIT) Antihistamine and Salbutamol
Anaphylaxis Acute illness 140 22th week (OIT) Adrenaline
OIT discontinued
5 No NA NA NA NA Desensitization
6 Urticaria and sickness No 18 12th week (O + OIT) Antihistamine
Corticosteroids
Failed
Urticaria No 7 15th week (O + OIT) Antihistamine
Urticaria No 4 20th week (O + OIT) Antihistamine
Anaphylaxis No 10 52th week (OIT) Adrenaline
OIT discontinued
7 No NA NA NA NA Desensitization
8 Anaphylaxis Acute illness 150 52th week (OIT) Adrenaline
OIT discontinued
Failed
  1. Abbreviations: NA not applicable, OIT oral immunotherapy